SERES THERAPEUTICS
(NASDAQ: MCRB)

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. It's SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.

0.916

-0.005 (-0.54%)
Range 0.915 - 0.962   (5.14%)
Open 0.932
Previous Close 0.921
Bid Price 5.020
Bid Volume 18
Ask Price 5.050
Ask Volume 32
Volume 2,746,107
Value -
Remark
Delayed prices. Updated at 21 Dec 2024 05:00.
Data powered by
View All Events

About SERES THERAPEUTICS

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. It's SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.

Loading Chart...

Please login to view stock data and analysis